StreetInsider.com News Articles

Form 10-K/A Adicet Bio, Inc. For: Dec 31

Wed, 20 May 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260520/26528416.html

Form 10-K/A Adicet Bio, Inc. For: Dec 31

Wed, 20 May 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260520/26528416.html

Form SCHEDULE 13G/A Adicet Bio, Inc. Filed by: Woodline Partners LP

Fri, 15 May 2026 09:11:00 -0400

si-local-file:///var/storage/secattach/20260515/26500600.html

Form SCHEDULE 13G/A Adicet Bio, Inc. Filed by: Woodline Partners LP

Fri, 15 May 2026 09:11:00 -0400

si-local-file:///var/storage/secattach/20260515/26500600.html

Adicet Bio to Participate in Fireside Chat at Jefferies Global Healthcare Conference

Thu, 14 May 2026 16:00:00 -0400

REDWOOD CITY, Calif.--(BUSINESS WIRE)-- Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference being held from June 2-4, 2026 in New York.

Details of the event are as follows:
Date: Thursday, June 4, 2026
Time: 7:35a.m. ET

The live audio webcast can be accessed on the Investors section of Adicet Bio’s website at http://www.adicetbio.com. An archived replay will

Adicet Bio to Participate in Fireside Chat at Jefferies Global Healthcare Conference

Thu, 14 May 2026 16:00:00 -0400

Details of the event are as follows:
Date: Thursday, June 4, 2026
Time: 7:35a.m. ET

The live audio webcast can be accessed on the Investors section of Adicet Bio’s website at http://www.adicetbio.com. An archived replay will

Adicet Bio to Participate in Fireside Chat at Jefferies Global Healthcare Conference

Thu, 14 May 2026 16:00:00 -0400

Details of the event are as follows:
Date: Thursday, June 4, 2026
Time: 7:35a.m. ET

The live audio webcast can be accessed on the Investors section of Adicet Bio’s website at http://www.adicetbio.com. An archived replay will

Adicet Bio to Participate in Fireside Chat at Jefferies Global Healthcare Conference

Thu, 14 May 2026 16:00:00 -0400

Details of the event are as follows:
Date: Thursday, June 4, 2026
Time: 7:35a.m. ET

The live audio webcast can be accessed on the Investors section of Adicet Bio’s website at http://www.adicetbio.com. An archived replay will

Form S-8 POS Adicet Bio, Inc.

Wed, 13 May 2026 17:16:00 -0400

si-local-file:///var/storage/secattach/20260513/26487514.html

Form S-8 POS Adicet Bio, Inc.

Wed, 13 May 2026 17:16:00 -0400

si-local-file:///var/storage/secattach/20260513/26487514.html

Adicet Bio (ACET) Misses Q1 EPS by 188c

Wed, 13 May 2026 17:10:06 -0400

Adicet Bio (NASDAQ: ACET) reported Q1 EPS of ($1.88).

For earnings history and earnings-related data on Adicet Bio (ACET) click here.

Form 10-Q Adicet Bio, Inc. For: Mar 31

Wed, 13 May 2026 16:33:00 -0400

si-local-file:///var/storage/secattach/20260513/26486813.html

Form 10-Q Adicet Bio, Inc. For: Mar 31

Wed, 13 May 2026 16:33:00 -0400

si-local-file:///var/storage/secattach/20260513/26486813.html

Form 8-K Adicet Bio, Inc. For: May 13

Wed, 13 May 2026 16:04:00 -0400

si-local-file:///var/storage/secattach/20260513/26485775.html

Form 8-K Adicet Bio, Inc. For: May 13

Wed, 13 May 2026 16:04:00 -0400

si-local-file:///var/storage/secattach/20260513/26485775.html

Adicet Bio Reports First Quarter 2026 Financial Results and Provides Business Updates

Wed, 13 May 2026 16:01:00 -0400

Clinical update anticipated in mid-2026 for Phase 1 autoimmune program evaluating prulacabtagene leucel (prula-cel, formerly ADI-001) with at least 20 lupus nephritis (LN) and systemic lupus erythematosus (SLE) patients with a minimum of six months follow-up

U.S. Food and Drug Administration (FDA) interaction to inform potential pivotal trial design for prula-cel expected in 2Q/2026

On track to submit regulatory filing for ADI-212 in metastatic castration-resistant prostate cancer (mCRPC) in 3Q/2026; enrollment expected to begin 4Q/2026, pending regulatory clearance

Continued advancement of cell therapy programs and differentiated in vivo CAR-T platform targeting multiple indications